Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,682,478
  • Shares Outstanding, K 56,195
  • Annual Sales, $ 26,820 K
  • Annual Income, $ -352,090 K
  • 60-Month Beta 0.84
  • Price/Sales 61.72
  • Price/Cash Flow N/A
  • Price/Book 2.03
Trade AGIO with:

Options Overview Details

View History
  • Implied Volatility 51.08% ( -5.32%)
  • Historical Volatility 55.10%
  • IV Percentile 63%
  • IV Rank 71.15%
  • IV High 70.85% on 06/13/23
  • IV Low 2.31% on 11/14/23
  • Put/Call Vol Ratio 24.31
  • Today's Volume 329
  • Volume Avg (30-Day) 322
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 10,452
  • Open Int (30-Day) 9,683

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.63
  • Number of Estimates 7
  • High Estimate -1.48
  • Low Estimate -1.78
  • Prior Year -1.47
  • Growth Rate Est. (year over year) -10.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.19 +11.84%
on 02/20/24
35.50 -17.49%
on 02/27/24
+2.78 (+10.49%)
since 02/16/24
3-Month
20.96 +39.74%
on 01/19/24
35.50 -17.49%
on 02/27/24
+6.04 (+25.98%)
since 12/18/23
52-Week
19.80 +47.97%
on 10/27/23
35.50 -17.49%
on 02/27/24
+6.03 (+25.92%)
since 03/17/23

Most Recent Stories

More News
Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Pharmaceuticals: Q3 Earnings Snapshot

AGIO : 29.29 (-2.17%)
Agios Pharmaceuticals: Q2 Earnings Snapshot

Agios Pharmaceuticals: Q2 Earnings Snapshot

AGIO : 29.29 (-2.17%)
Why Shares of Schrödinger Rose This Week

Interest in the company's AI platform continues to drive the stock.

AGIO : 29.29 (-2.17%)
GS : 384.37 (-0.73%)
SDGR : 25.68 (-1.38%)
Wall Street Analysts Predict a 42.46% Upside in Agios Pharmaceuticals (AGIO): Here's What You Should Know

The consensus price target hints at a 42.5% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

AGIO : 29.29 (-2.17%)
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.

AGIO : 29.29 (-2.17%)
ADAP : 1.4700 (-0.68%)
SPRO : 1.7300 (-3.35%)
LSTA : 3.04 (-1.30%)
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.53% and 4.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AGIO : 29.29 (-2.17%)
IMCC : 0.3194 (-13.49%)
Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Pharmaceuticals: Q1 Earnings Snapshot

AGIO : 29.29 (-2.17%)
Baxter International (BAX) Q1 Earnings and Revenues Top Estimates

Baxter (BAX) delivered earnings and revenue surprises of 22.92% and 1.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BAX : 41.54 (-0.17%)
AGIO : 29.29 (-2.17%)
Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

/PRNewswire/ -- Totus Medicines, the drug discovery and development company committed to ending the era of untreatable disease, announced today the appointment...

AGIO : 29.29 (-2.17%)
Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AGIO : 29.29 (-2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 30.94
2nd Resistance Point 30.47
1st Resistance Point 29.88
Last Price 29.29
1st Support Level 28.82
2nd Support Level 28.35
3rd Support Level 27.76

See More

52-Week High 35.50
Fibonacci 61.8% 29.50
Last Price 29.29
Fibonacci 50% 27.65
Fibonacci 38.2% 25.79
52-Week Low 19.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar